Moderna Therapeutics, the subject of the largest ever biotech private equity fundraising of $450m earlier this month (scripintelligence.com, 6 January 2015), has signed a license and collaboration agreement with Merck & Co for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA).
Moderna's work in the collaboration will be led by Valera, its subsidiary entirely focused on the development of mRNA vaccines and therapeutics for infectious disease.
